INT204929

Context Info Confidence 0.08 First Reported 2003 Last Reported 2009 Negated 0 Speculated 0 Reported most in Body Documents 18 Total Number 18 Disease Relevance 4.74 Pain Relevance 0.70

extracellular space (IL33) extracellular region (IL33)

Anatomy Link Frequency gray matter 3 D17 1 plasma 1 IL33 (Homo sapiens)

Pain Link Frequency Relevance Heat imagery 54 91.44 Bioavailability 3 89.76 amygdala 108 88.96 cva 4 87.16 Duloxetine 36 81.68 Desipramine 9 78.40 abdominal pain 8 76.00 Inflammation 11 72.20 depression 168 66.84 Pain 24 56.20

Disease Link Frequency Relevance Heat Handedness 132 99.96 Disease Progression 8 99.80 Mouth Disease 65 99.74 Hepatitis 48 96.80 Gastroenteritis 41 93.28 Infection 42 87.72 Hemorrhage 4 87.16 Viral Infection 32 86.92 Heart Rate Under Development 4 86.52 Disorder Of Lipid Metabolism 18 85.52

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

DVS sustained release was considered safe in healthy volunteers up to a single dose of 750 mg27 and was well tolerated in multiple doses up to 450 mg.28 The plasma protein binding of DVS is low (30%) and is independent of drug concentration.

DVS Binding (binding) of in plasma

1) Confidence 0.08 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.06 Pain Relevance 0.31

Data pooled from 7 clinical trials, showed that treatment with DVS was associated with small mean decreases in weight in the short term (1 kg), which persisted up to 6 months with a small mean increase (<1 kg) and was comparable to placebo.46

DVS Binding (treatment) of

2) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.31 Pain Relevance 0

The change on HAM-D17 total score from baseline was greater for DVS than for placebo, with a magnitude of effect = ?

DVS Binding (greater) of in D17

3) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.42 Pain Relevance 0.03

Four deaths (two HFMD and two non-HFMD cases) were associated with HEV71.

HEV71 Binding (associated) of associated with mouth disease

4) Confidence 0.03 Published 2003 Journal Emerging Infectious Diseases Section Body Doc Link PMC2873753 Disease Relevance 1.83 Pain Relevance 0.04

These mutants were found to lack the ability to interact with HEV-neutralizing monoclonal antibody, mAb 8C11 (Figure 5).

HEV Binding (interact) of

5) Confidence 0.03 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0 Pain Relevance 0

Taken together the presence of neutralizing antibody binding sites of HEV on E2s, and the shape of the dimer, we suggest that E2s is present on the surface protrusions of HEV shown in the electron microscopic structure [5].

HEV Binding (binding) of

6) Confidence 0.03 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0.06 Pain Relevance 0

To verify that the dimerization of E2s is crucial for the host interaction of HEV, several mutations on dimer interface regions of E2/E2s were carried out (Figures 5 and 6), and their roles in destabilizing the dimer formation were studied.

HEV Binding (interaction) of

7) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0.25 Pain Relevance 0

HEV antibody recognition and E2s

HEV Binding (recognition) of

8) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0.07 Pain Relevance 0

Moreover, two of 13 linear epitope-reactive antibodies and 15 of 20 conformational determinant -reactive antibodies can bind genotype I and/or genotype IV HEV.

HEV Binding (bind) of

9) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0 Pain Relevance 0

Monoclonal antibodies reactive against the abovementioned regions bind to live HEV, and at least two monoclonal antibodies (8C11 and 8H3) could neutralize the infectivity of HEV [8].

HEV Binding (bind) of

10) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0.08 Pain Relevance 0

Neutralizing antibodies such as 8C11 and 8H3 bind with native HEV [8], as well as with the dimeric form of E2 constructs [6],[19].

HEV Binding (bind) of

11) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0.26 Pain Relevance 0

This article reports the crystal structure of the HEV capsid protein domain E2s (protruding domain), along with functional studies, which illustrate the tight homodimeric state of E2s and that dimerization is essential for both HEV–host interactions and disease progression.

HEV Binding (interactions) of associated with disease progression

12) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Abstract Doc Link PMC2714988 Disease Relevance 0.84 Pain Relevance 0.11

Together, gender, HEV, and gender × HEV interaction were able to account for about 60% of the individual variation in measures of gray matter volume.

HEV Binding (interaction) of in gray matter

13) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1820787 Disease Relevance 0 Pain Relevance 0

Together, gender, HEV, and gender × HEV interaction were able to account for about 60% of the individual variation in measures of gray matter volume.

HEV Binding (interaction) of in gray matter

14) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1820787 Disease Relevance 0 Pain Relevance 0

Overall, the interaction between gender and HEV had an eta-squared of 0.39 on total GMV.

HEV Binding (interaction) of

15) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1820787 Disease Relevance 0 Pain Relevance 0

There was a strong interaction between HEV-laterality and gender, which together accounted for 60% of individual variability in total grey matter volume (GMV).

HEV Binding (interaction) of in grey matter associated with handedness

16) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Abstract Doc Link PMC1820787 Disease Relevance 0.44 Pain Relevance 0.04

However, there were even more marked interactions between HEV and gender.

HEV Binding (interactions) of

17) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1820787 Disease Relevance 0.06 Pain Relevance 0

In contrast, direction of HEV, gender, and their interaction accounted for up to 60% of the variance.

HEV Binding (interaction) of

18) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1820787 Disease Relevance 0.07 Pain Relevance 0.16

General Comments

This test has worked.